| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Absorption, metabolism, and excretion of oral [14C] radiolabeled donafenib: an open-label, phase I, single-dose study in humans
|
Ma, Sheng
|
|
|
95 |
1 |
|
artikel
|
| 2 |
Absorption, single-dose and steady-state metabolism, excretion, and pharmacokinetics of adagrasib, a KRASG12C inhibitor
|
Rahbaek, Lisa
|
|
|
95 |
1 |
|
artikel
|
| 3 |
A case report: capillary leak syndrome in a patient receiving high-dose methotrexate, Tislelizumab and zanubrutinib for CNS lymphoma
|
Li, Wenpeng
|
|
|
95 |
1 |
|
artikel
|
| 4 |
A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome
|
Maher, Keri R.
|
|
|
95 |
1 |
|
artikel
|
| 5 |
Clinical relevance of Nectin-4 downregulation and biological changes caused by cytotoxic chemotherapy in bladder cancer
|
Miyake, Makito
|
|
|
95 |
1 |
|
artikel
|
| 6 |
Dihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing
|
Shamaei Zadeh, Alexia
|
|
|
95 |
1 |
|
artikel
|
| 7 |
DNA-incorporated thioguanine to detect potential non-adherence to maintenance therapy in acute lymphoblastic leukemia
|
Koch, Mathilde Rønne
|
|
|
95 |
1 |
|
artikel
|
| 8 |
Dose adjustment strategy for high-dose methotrexate-induced toxicities in pediatric acute lymphoblastic leukemia: based on population PK analysis and exposure-toxicity relationship
|
Cao, Ailing
|
|
|
95 |
1 |
|
artikel
|
| 9 |
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)
|
Taylor, Sarah E.
|
|
|
95 |
1 |
|
artikel
|
| 10 |
DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy
|
Vilquin, Paul
|
|
|
95 |
1 |
|
artikel
|
| 11 |
Effect of Metformin on vascular endothelial injury in patients with non-small cell lung cancer treated with chemotherapy combined with bevacizumab
|
Li, Hongyan
|
|
|
95 |
1 |
|
artikel
|
| 12 |
Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study
|
Cheng, Ching-Yuan
|
|
|
95 |
1 |
|
artikel
|
| 13 |
ETV1 genetic polymorphisms as a candidate prognosis biomarker of Gastrointestinal stromal tumor
|
Zhuang, Wei
|
|
|
95 |
1 |
|
artikel
|
| 14 |
Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment
|
Cheng, Yiming
|
|
|
95 |
1 |
|
artikel
|
| 15 |
Evaluation of urinary vanin-1 for the early prediction of cisplatin-induced acute kidney injury during neoadjuvant chemotherapy for esophageal cancer
|
Uchino, Tomonobu
|
|
|
95 |
1 |
|
artikel
|
| 16 |
Evolution of computational techniques against various KRAS mutants in search for therapeutic drugs: a review article
|
Mehmood, Ayesha
|
|
|
95 |
1 |
|
artikel
|
| 17 |
Food effect trial of the pharmacokinetics and safety of TQ05105 in healthy Chinese subjects
|
Dai, Jun
|
|
|
95 |
1 |
|
artikel
|
| 18 |
From predictive biomarker to therapeutic target: the dual role of SLFN11 in chemotherapy sensitivity
|
Feng, Yue
|
|
|
95 |
1 |
|
artikel
|
| 19 |
HER-2 SMASH
|
Alandağ, Celal
|
|
|
95 |
1 |
|
artikel
|
| 20 |
HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC
|
Funaishi, Kunihiko
|
|
|
95 |
1 |
|
artikel
|
| 21 |
Impact of altitude on hemoglobin dynamics and prognosis in patients with advanced hepatocellular carcinoma receiving antiangiogenic TKIs: A propensity score matched study
|
Zhou, Mengyun
|
|
|
95 |
1 |
|
artikel
|
| 22 |
Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia
|
Mangoura, Safwat A.
|
|
|
95 |
1 |
|
artikel
|
| 23 |
Influence of DPYD gene polymorphisms on 5-Fluorouracil toxicities in Thai colorectal cancer patients
|
Atasilp, Chalirmporn
|
|
|
95 |
1 |
|
artikel
|
| 24 |
Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma: a case report
|
Gezelius, Emelie
|
|
|
95 |
1 |
|
artikel
|
| 25 |
Landscape analysis of adverse events and dose intensity for FDA approved oncology small molecules
|
Collins, Keagan P.
|
|
|
95 |
1 |
|
artikel
|
| 26 |
Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1)
|
Ri, Masaki
|
|
|
95 |
1 |
|
artikel
|
| 27 |
Nanotechnology and nanobots unleashed: pioneering a new era in gynecological cancer management – a comprehensive review
|
Kumar, Naina
|
|
|
95 |
1 |
|
artikel
|
| 28 |
Neurofilament light chain as a marker for neuronal damage: integrating in vitro studies and clinical findings in patients with oxaliplatin-induced neuropathy
|
Gehr, Nina Lykkegaard
|
|
|
95 |
1 |
|
artikel
|
| 29 |
New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis
|
Balis, Frank M.
|
|
|
95 |
1 |
|
artikel
|
| 30 |
Novel desensitization protocol utilizing conventional formulations to mitigate Temozolomide-Related skin hypersensitivity
|
Cantley, Morgan E.
|
|
|
95 |
1 |
|
artikel
|
| 31 |
Pazopanib and antacids: insights from the WHO pharmacovigilance database
|
Nishida, Kazuki
|
|
|
95 |
1 |
|
artikel
|
| 32 |
Peptides derived from the POU domain of BRN2 show antitumor activity against murine melanoma model cells in vitro and in vivo
|
Cesar, Maria Carolina Mariano
|
|
|
95 |
1 |
|
artikel
|
| 33 |
Pharmacokinetic analysis of crushed venetoclax tablets combined with azacitizine for recurrent pediatric acute myeloid leukemia (AML)
|
Matsui, Motohiro
|
|
|
95 |
1 |
|
artikel
|
| 34 |
Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma
|
Meertens, Marinda
|
|
|
95 |
1 |
|
artikel
|
| 35 |
Pharmacokinetic profile of novel reduced-dose Danziten™ (nilotinib tablets) versus Tasigna® (nilotinib capsules): in vivo bioequivalence and population pharmacokinetic analysis
|
Mauro, Michael
|
|
|
95 |
1 |
|
artikel
|
| 36 |
Pharmacokinetics, mass balance, and metabolism of [14C]FCN-437c, a selective and potent CDK4/6 inhibitor in humans
|
Gao, Lei
|
|
|
95 |
1 |
|
artikel
|
| 37 |
Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans
|
Liu, Donghui
|
|
|
95 |
1 |
|
artikel
|
| 38 |
Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding
|
Tachibana, Masaya
|
|
|
95 |
1 |
|
artikel
|
| 39 |
Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy
|
Zhang, Tao
|
|
|
95 |
1 |
|
artikel
|
| 40 |
Pharmacokinetics, safety, and tolerability of fedratinib in adults with moderate and severe hepatic impairment: results from the phase 1 FEDR-CP-001 trial
|
Chen, Yizhe
|
|
|
95 |
1 |
|
artikel
|
| 41 |
Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)
|
Krishnamurthy, Anuradha
|
|
|
95 |
1 |
|
artikel
|
| 42 |
Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas
|
O’Sullivan Coyne, Geraldine
|
|
|
95 |
1 |
|
artikel
|
| 43 |
Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration
|
Matheux, Alice
|
|
|
95 |
1 |
|
artikel
|
| 44 |
Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer
|
Abegesah, Aburough
|
|
|
95 |
1 |
|
artikel
|
| 45 |
Potential anticancer effects of sodium-glucose cotransporter protein 2 (SGLT2) inhibitors Canagliflozin and Dapagliflozin
|
Dong, Weiyu
|
|
|
95 |
1 |
|
artikel
|
| 46 |
Potential role of endothelial dysfunction in hypertension and proteinuria in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab: a pilot prospective observational study
|
Nihei, Satoru
|
|
|
95 |
1 |
|
artikel
|
| 47 |
Predictive factors for first dose reduction and interruption of lenvatinib after beginning of the standard dose in Japanese patients with thyroid cancer
|
Fujita, Kazuma
|
|
|
95 |
1 |
|
artikel
|
| 48 |
Protective effect of celecoxib against capecitabine induced hand and foot syndrome in patients with colorectal Cancer
|
Kettana, Ahmed M.
|
|
|
95 |
1 |
|
artikel
|
| 49 |
Retraction Note: Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma
|
Zhang, Hui
|
|
|
95 |
1 |
|
artikel
|
| 50 |
Risk factors and prediction models for cardiotoxicity induced by anthracyclines in malignant chemotherapy
|
Zhang, Pengxiang
|
|
|
95 |
1 |
|
artikel
|
| 51 |
Sulforaphane inhibits multiple myeloma cell-induced osteoclast differentiation and macrophage proliferation by elevating ferroportin1
|
Sun, Weichu
|
|
|
95 |
1 |
|
artikel
|
| 52 |
Targeting insulin-like growth factor-1 (IGF-1) by using metformin in non-diabetic metastatic breast cancer female patients: a randomized controlled trial
|
Salah, Hager
|
|
|
95 |
1 |
|
artikel
|
| 53 |
Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma
|
Zheng, Kewei
|
|
|
95 |
1 |
|
artikel
|
| 54 |
Tenuigenin inhibits osteosarcoma growth via CIP2A/PP2A/NF-κB axis
|
Yang, Shuo
|
|
|
95 |
1 |
|
artikel
|
| 55 |
Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial)
|
Hanrath, Maarten A.
|
|
|
95 |
1 |
|
artikel
|
| 56 |
Trends in renal function following vascular endothelial growth factor inhibitor administration in patients with cancer and diabetes mellitus
|
Shibutani, Yuma
|
|
|
95 |
1 |
|
artikel
|
| 57 |
Unrecognized mutations in DPYD* 2 A wild-type rectal cancer patients receiving postoperative 5-FU-based chemotherapy - do they have a clinical impact?
|
Liersch, P.
|
|
|
95 |
1 |
|
artikel
|
| 58 |
Variations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment
|
Sato, Miki Takenaka
|
|
|
95 |
1 |
|
artikel
|
| 59 |
WT161, a selective HDAC6 inhibitor, decreases growth, enhances chemosensitivity, promotes apoptosis, and suppresses motility of melanoma cells
|
Oliveira-Silva, João Marcos
|
|
|
95 |
1 |
|
artikel
|
Tijdschrift beschrijving